Winway Health Desk
Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with...
When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule...
The shift to value-based care has accelerated in the wake of...
The Covid-19 pandemic has exposed weaknesses in health care systems around the world, and the U.S. is no exception. Observers cite a wide range...
Women’s health startup Tia strikes partnership with CommonSpirit
Tia’s first clinic in New York. It plans to open a clinic in Phoenix later this year through a partnership with CommonSpirit. Photo credit:...
Genentech aims high with new diversity goals, including doubling hires and...
Roche’s Genentech knows diversity and inclusion aren’t just good for society, they're good for business.
That's why its new strategic plan includes doubling the number of Black...
Survey: 1 in 5 Americans can’t afford necessary care
A staggering 46 million people — nearly one-fifth of all Americans — cannot afford necessary healthcare services, according to a new survey.
Conducted by West...
FDA downplayed serious red flags at Merck vaccine plant slated for...
An FDA inspector-turned-whistleblower claims the agency soft-pedaled violations at a range of pharma manufacturing plants, including a Merck & Co. vaccine facility in Durham,...
Telehealth aside, providers look to invest IT dollars in cloud services,...
Provider IT spending is expected to grow from $113 billion last year to $131 billion in 2022, according to data from Gartner. This huge...
Apotex yanks ADHD med after traces of schizophrenia drug turn up...
When traces of the wrong drug appear in a tablet, it's best to err on the side of caution. Apotex did just that Wednesday, when...
IQVIA pays Quest Diagnostics $760M to get full control of central...
The laboratory services joint venture that IQVIA and Quest Diagnostics have operated for the past six years is moving under the full control of...
Bristol Myers’ Abecma launch tools? Digital CAR-T platform and provider training,...
With a nod for CAR-T Abecma finally in hand, Bristol Myers Squibb now faces an almost equally difficult challenge—launching the complex multiple myeloma treatment.
Its first priority?...
